本文選題：宮頸癌 + SAHA�。� 參考：《深圳大學(xué)》2017年碩士論文

【摘要】：宮頸癌(cervical cancer)是女性宮頸上皮細(xì)胞癌變而形成的腫瘤,是全球女性最常見的惡性腫瘤之一,發(fā)病率位居惡性腫瘤第二位。同時(shí),宮頸癌的發(fā)病率在中國居于第一的位置,死亡率位居第二。有研究資料顯示,宮頸癌的發(fā)病率正在以每年2%-3%的速度迅速增長。發(fā)達(dá)國家宮頸癌的防治經(jīng)驗(yàn)表明,通過對易發(fā)人群的密切篩查和早期預(yù)防,宮頸癌的發(fā)病率可以降低70%-90%。因此,研究宮頸癌的發(fā)病的分子機(jī)制,篩查和防治宮頸癌的發(fā)生,是世界宮頸癌研究和防治中最為艱巨和緊迫的課題。目前宮頸癌的臨床治療方法主要以手術(shù)治療輔以化學(xué)治療療和放射治療及分子靶向治療,雖然近幾十年來宮頸癌的臨床治療取得了長足進(jìn)步,早期患者采用手術(shù)或放療,能夠取得較好的療效,但對于中晚期宮頸癌患者,手術(shù)操作難度較大。并且,傳統(tǒng)的化療藥物在殺傷腫瘤細(xì)胞的同時(shí),也殺傷大量的正常細(xì)胞,使患者產(chǎn)生較嚴(yán)重的不良反應(yīng)。同時(shí),隨著化療的繼續(xù),化療藥物的耐藥性問題也常使化療效果難以達(dá)到預(yù)期。因此在宮頸癌的傳統(tǒng)治療模式中,發(fā)展更有效的治療藥物與方法成為新的研究課題。本課題以人宮頸癌HeLa細(xì)胞為研究對象,研究組蛋白去乙酰化酶抑制劑SAHA聯(lián)合紫杉醇對宮頸癌He La細(xì)胞的體外殺傷效果。MTT法檢測宮頸癌HeLa細(xì)胞增殖情況,分別用SAHA、紫杉醇、SAHA+紫衫醇處理HeLa細(xì)胞24h、48h后,發(fā)現(xiàn)相較于SAHA(53.62±3.66%、34.74±3.03%)和紫杉醇(74.07±5.32%、70.88±3.09%)單獨(dú)使用組,SAHA與紫衫醇聯(lián)合使用(45.73±4.02%、22.98±3.86%)組的HeLa細(xì)胞存活率更低,能夠顯著抑制He La細(xì)胞的增殖。采用SPSS16.0計(jì)算SAHA增敏前后紫杉醇對He La細(xì)胞IC50的影響,結(jié)果顯示SAHA增敏后,紫杉醇對He La細(xì)胞24h的半數(shù)致死劑量由(18.023±1.256)nM降低到(8.887±0.949)nM,48h的半數(shù)致死劑量由(12.119±1.083)n M降低到(3.994±0.601)nM,SAHA能夠顯著降低紫杉醇對HeLa細(xì)胞的IC50(P0.01);利用流式細(xì)胞術(shù)檢測He La細(xì)胞的凋亡率,結(jié)果顯示SAHA組、紫杉醇組及SAHA與紫杉醇聯(lián)合用藥組的HeLa細(xì)胞的凋亡率分別為(6.44±0.86)%,(7.23±1.49)%,(16.22±3.38)%,聯(lián)合用藥組HeLa細(xì)胞的凋亡率分別高于紫杉醇組、SAHA組(P0.05,P0.05),SAHA與紫杉醇聯(lián)合可以顯著增加HeLa細(xì)胞的凋亡率,提高誘導(dǎo)HeLa細(xì)胞凋亡的能力;利用流式細(xì)胞術(shù)檢測HeLa細(xì)胞周期,發(fā)現(xiàn)單獨(dú)SAHA處理24h的HeLa細(xì)胞主要處于G0/G1期(90.07±1.39)%,S期(3.88±1.47)%,單獨(dú)紫杉醇的HeLa細(xì)胞主要處于G0/G1期(33.48±6.64)%,S期(40.77±4.43)%,SAHA聯(lián)合紫杉醇的HeLa細(xì)胞主要處于G0/G1期(84.22±2.07)%,S期(11.67±1.28)%,提示SAHA與紫杉醇聯(lián)合使用能夠抑制HeLa細(xì)胞有絲分裂過程中的DNA合成和復(fù)制;利用流式細(xì)胞儀檢測HeLa細(xì)胞中活性氧(ROS)水平,對照組、SAHA、紫杉醇和SAHA+紫杉醇組處理24h后的He La細(xì)胞的ROS水平分別為(1.65±0.84)%、(35.19±4.23)%、(27.26±3.74)%和(44.04±10.77)%,SAHA+紫杉醇組中ROS水平明顯升高,且相較于紫杉醇組具有統(tǒng)計(jì)學(xué)意義(P0.05);免疫熒光法標(biāo)記HeLa細(xì)胞微管和DNA,發(fā)現(xiàn)SAHA和紫杉醇聯(lián)合處理24h后的HeLa細(xì)胞的微管呈短小纖細(xì),并向細(xì)胞核聚集;RT-PCR檢測P27抑癌基因mRNA的表達(dá)情況,發(fā)現(xiàn)紫杉醇組、SAHA組以及SAHA和紫杉醇聯(lián)合用藥組的HeLa細(xì)胞中抑癌基因p27基因的mRNA相對表達(dá)量分別為0.978±0.117,5.845±0.548和10.601±0.673,聯(lián)合用藥組相對表達(dá)量均高于紫杉醇組、SAHA組,具有統(tǒng)計(jì)學(xué)意義(P0.001,P0.001);Western blot檢測凋亡相關(guān)蛋白(caspase-3和caspase-9)和乙�；M蛋白(Ac-H4)的表達(dá)情況,發(fā)現(xiàn)SAHA+紫杉醇能夠激活caspase-3和caspase-9蛋白,增強(qiáng)組蛋白H4的乙酰化水平。綜上所述,在體外培養(yǎng)條件下,SAHA與紫杉醇聯(lián)合作用于宮頸癌HeLa細(xì)胞時(shí),通過激活caspase蛋白途徑、提高細(xì)胞內(nèi)活性氧ROS水平、上調(diào)p27抑癌基因的表達(dá)、增強(qiáng)組蛋白H4的乙�；胶陀绊懳⒔z微管的結(jié)構(gòu)和功能,從而誘導(dǎo)細(xì)胞凋亡,抑制細(xì)胞增殖,阻滯細(xì)胞周期,最終在增強(qiáng)抗腫瘤的能力的同時(shí)減輕化療藥物的副作用。
[Abstract]:Cervical cancer (cervical cancer) is a tumor formed by canceration of cervical epithelial cells in women. It is one of the most common malignant tumors in women all over the world. The incidence of cancer is the second most malignant tumor. At the same time, the incidence of cervical cancer is the first in China and the mortality rate ranks second. The rate of 2%-3% is increasing rapidly in the year. The experience of prevention and control of cervical cancer in developed countries shows that the incidence of cervical cancer can be reduced by close screening and early prevention. The molecular mechanism of the study of cervical cancer, screening and preventing the occurrence of cervical cancer are the most arduous in the research and prevention of cervical cancer in the world. At present, the clinical treatment of cervical cancer is mainly based on surgical treatment, chemotherapy, radiotherapy and molecular targeting therapy. Although the clinical treatment of cervical cancer has made great progress in recent decades, early patients with surgery or radiotherapy can achieve better curative effect, but for patients with middle and late cervical cancer, hand It is difficult to operate, and the traditional chemotherapeutic drugs kill the tumor cells and kill a large number of normal cells, so that the patients produce more serious adverse reactions. At the same time, with the continuation of chemotherapy, the drug resistance of chemotherapeutic drugs often makes the effect of chemotherapy difficult to achieve expectations. More effective therapeutic drugs and methods have become a new research topic. In this study, human cervical cancer HeLa cells were used to study the killing effect of histone deacetylase inhibitor SAHA combined with taxol on cervical cancer He La cells in vitro.MTT assay for the proliferation of cervical cancer HeLa cells, respectively, SAHA, paclitaxel, and SAHA+ After 24h and 48h, HeLa cells were found to be compared to SAHA (53.62 + 3.66%, 34.74 + 3.03%) and paclitaxel (74.07 + 5.32%, 70.88 + 3.09%) alone. The survival rate of HeLa cells in the group of SAHA and the combined use of (45.73 + 4.02%, 22.98 + 3.86%) group was lower, and the proliferation of He La cells could be suppressed significantly. SPSS16.0 calculation of paclitaxel before and after SAHA sensitization to SAHA was used. The effect of IC50 in He La cells showed that after SAHA sensitization, the median lethal dose of paclitaxel to He La cell 24h decreased from (18.023 + 1.256) nM to (8.887 + 0.949) nM, and the median lethal dose of 48h decreased from (12.119 + 1.083) n M to (3.994 + 0.601). The apoptosis rate of He La cells was measured. The results showed that the apoptosis rate of HeLa cells in group SAHA, paclitaxel group and SAHA and paclitaxel group was (6.44 + 0.86)%, (7.23 + 1.49)%, (16.22 + 3.38)%. The apoptosis rate of HeLa cells in combination group was higher than that of paclitaxel group, SAHA group (P0.05, P0.05), SAHA and paclitaxel could significantly increase HeLa. The apoptotic rate of cells increased the ability to induce apoptosis of HeLa cells, and HeLa cell cycle was detected by flow cytometry. The HeLa cells treated with single SAHA for 24h were mainly in G0/G1 phase (90.07 + 1.39)%, S phase (3.88 + 1.47)%, and HeLa cells of taxol alone in G0/G1 (33.48 + 6.64)%, S (40.77. 4.43)%, SAHA with paclitaxel HeL A cells were mainly in phase G0/G1 (84.22 + 2.07)% and S phase (11.67 + 1.28)%. The combination of SAHA and taxol could inhibit the synthesis and replication of DNA during the mitosis of HeLa cells, and the level of reactive oxygen (ROS) in HeLa cells was detected by flow cytometry. The control group, SAHA, paclitaxel and SAHA+ paclitaxel group treated 24h He cells The level of (1.65 + 0.84)%, (35.19 + 4.23)%, (27.26 + 3.74)% and (44.04 + 10.77)%, ROS level in SAHA+ paclitaxel group increased significantly, and compared with paclitaxel group (P0.05). The immunofluorescence method labeled HeLa cell microtubules and DNA, and the microtubules of HeLa cells after SAHA and paclitaxel combined with 24h were small and thin. The expression of P27 suppressor gene mRNA was detected by RT-PCR. The relative expression of the mRNA relative expression of the tumor suppressor gene p27 gene in the paclitaxel group, the SAHA group and the SAHA and paclitaxel group HeLa cells was 0.978 + 0.117,5.845 + 0.548 and 10.601 + 0.673 respectively. The relative expression of the combined drug group was higher than that of the paclitaxel group, the SAHA group, It was statistically significant (P0.001, P0.001); Western blot detected the expression of apoptosis related proteins (caspase-3 and caspase-9) and acetylation histone (Ac-H4). It was found that SAHA+ paclitaxel could activate caspase-3 and caspase-9 proteins and enhance the level of acetylation of histone H4. Under the conditions of culture, SAHA and taxol were combined in vitro. When used for cervical cancer HeLa cells, by activating the caspase protein pathway, increasing the intracellular reactive oxygen ROS level, up regulation of the expression of p27 suppressor gene, enhancing the level of acetylation of histone H4 and influencing the structure and function of microtubule microtubule, inducing cell apoptosis, inhibiting cell proliferation, blocking cell cycle, and finally enhancing the ability of anti-tumor. It also alleviated the side effects of chemotherapeutic drugs.
【學(xué)位授予單位】：深圳大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 施資堅(jiān);朱俊山;任帥;歐陽東云;何賢輝;;組蛋白去乙�；敢种苿㏒AHA對小鼠淋巴細(xì)胞增殖和凋亡的影響[J];現(xiàn)代免疫學(xué);2012年01期

2 于濤;張鵬;鹿全意;劉銀梅;;組蛋白去乙酰化酶抑制劑SAHA誘導(dǎo)骨髓瘤細(xì)胞的凋亡[J];中國組織工程研究;2012年06期

3 Richon V.;朱國興;;通過組蛋白去乙�；敢种苿㏒AHA選擇性誘導(dǎo)皮膚T細(xì)胞淋巴瘤細(xì)胞凋亡:相關(guān)的治療作用機(jī)制[J];世界核心醫(yī)學(xué)期刊文摘(皮膚病學(xué)分冊);2006年08期

4 謝莉;何振華;張秀峰;;SAHA對TGF-β1誘導(dǎo)的人胚肺成纖維細(xì)胞膠原蛋白表達(dá)的影響[J];中南醫(yī)學(xué)科學(xué)雜志;2013年03期

5 龔愛華;熊二夢;張嚴(yán);杜鳳移;彭琬昕;邵根寶;金潔;程建軍;;組蛋白去乙酰化酶抑制劑SAHA影響U251細(xì)胞中p21穩(wěn)定性的機(jī)制[J];中國細(xì)胞生物學(xué)學(xué)報(bào);2013年11期

6 聶建云;陳楊萍;黃云超;;辛二酰苯胺異羥肟酸(SAHA)對乳腺癌細(xì)胞增殖影響的動物實(shí)驗(yàn)研究[J];實(shí)用癌癥雜志;2011年03期

7 龔愛華;熊二夢;張嚴(yán);杜鳳移;彭琬昕;邵根寶;金潔;程建軍;;SAHA誘導(dǎo)的p21表達(dá)致U251MG細(xì)胞抗凋亡效應(yīng)[J];中國藥理學(xué)通報(bào);2013年12期

8 張海元;張靜;劉康兵;;去乙酰酶抑制劑SAHA增強(qiáng)順鉑抗肝癌細(xì)胞活性研究[J];長江大學(xué)學(xué)報(bào)(自然科學(xué)版);2011年08期

9 伊鐵忠;陳星;于紅麗;糜若然;鄭建華;;VPA和SAHA對內(nèi)膜癌細(xì)胞凋亡和E-cad基因表達(dá)影響[J];中國腫瘤臨床;2009年19期

10 樓煒;劉斌;宋宜;;SAHA對p53野生型及敲低的腫瘤細(xì)胞體外抑制效應(yīng)[J];醫(yī)藥導(dǎo)報(bào);2009年05期

相關(guān)會議論文 前1條

1 張?zhí)?車敦發(fā);;SAHA綜合征研究進(jìn)展[A];2012全國中西醫(yī)結(jié)合皮膚性病學(xué)術(shù)會議論文匯編[C];2012年

相關(guān)碩士學(xué)位論文 前4條

1 王雯雯;組蛋白去乙�；敢种苿㏒AHA對肝星狀細(xì)胞激活相關(guān)生物學(xué)特征的影響及其分子機(jī)制的研究[D];南通大學(xué);2014年

2 劉好;組蛋白去乙酰化酶抑制劑SAHA聯(lián)合紫杉醇抑制宮頸癌HeLa細(xì)胞的體外實(shí)驗(yàn)研究[D];深圳大學(xué);2017年

3 陳粼波;組蛋白去乙�；敢种苿㏒AHA對人臍靜脈內(nèi)皮細(xì)胞血管生成的抑制及其初步機(jī)制[D];重慶醫(yī)科大學(xué);2013年

4 張?zhí)?SAHA綜合征臨床和實(shí)驗(yàn)室特征及中醫(yī)分型研究[D];南京中醫(yī)藥大學(xué);2012年

，

本文編號：2083842